Annovis Bio schedules corporate update webinar for next week

·26 Aug
Share:PostShare

26 August 2026 - Annovis Bio Inc (NYSE:ANVS), a Phase 3 clinical-stage biotechnology company developing an investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer�...

M

M2 Pharma

Original source

Read full story

Related Stories

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer